Pfizer

Scott Gottlieb joins Pfizer's board

Scott Gottlieb speaks at a public event.
Scott Gottlieb is getting closer to the industry he regulated. Photo: Chuck Kennedy for Axios

Pfizer, which has clashed with President Trump over drug prices, has appointed former FDA commissioner Scott Gottlieb to its board of directors. The role pays $335,000 annually in cash and stock.

The big picture: Since leaving the Trump administration roughly 3 months ago, Gottlieb has rejoined a conservative think tank and a venture capital firm that has pharmaceutical investments. Cycling between public office and well-paying private sector companies has become commonplace among FDA officials as well as other top health agency leaders.

CDC walks back pneumonia vaccine recommendation for seniors

A box of Prevenar 13, a pneumonia vaccine made by Pfizer.
A European box of Pfizer's pneumococcal vaccine. Photo: Fred Tanneau/AFP via Getty Images

In a narrow 8-6 vote today, a federal vaccine advisory panel shot down its 2014 recommendation that all adults 65 and older get a pneumococcal vaccine called Prevnar 13. Instead, the panel said seniors should get the vaccine based on conversations with their clinicians.

Why it matters: Seniors can still get the shot, but the vaccine won't be universally recommended — to the dismay of the vaccine makers. Pfizer sells Prevnar 13, and the drug company's stock shot down 2% once investors learned of the vote.